John Gillard: Yes. Paul, no, I would be hopeful that we will continue to see that type of margin come through. As I mentioned, we made some price increases second half of 2022, sometimes take some time for those to roll-through. We have some other price increases. We expect to push through now in quarter two of this year and that we are significantly focusing on reducing down our costs, right. So, between the two of those activities, I do expect that we would be able to maintain margins in around that 40% level. Some will depend on product mix. So, for example, as we place an increased amount of , as you know, our margin on them is typically high margin consumer revenue as we go forward, right. So, do I think that number will be 40% every quarter?
Probably not, but for us, we’re happy to take an element of variability, particularly around hemoglobin instruments placements as they generally deliver, which higher quality revenue both in terms of margin and predictability as we go forward. And also, look at TrinScreen, this is €“ it could be interesting to see what impact that has in terms of our margin as well and how big those numbers get. Some unknowns within that, but we’re certainly much happier with the trends we’re seeing now in terms of margin given the hard work and the actions that people have taken over the last 6 months.
Paul Nouri: Okay. And then last question is around the strategic investment for imaware. Maybe, a, if you could give us the size of the overall money raise that they did? And then b, what their particular competitive advantage is in this space? And I’m kind of assuming that they’re using your lab as the exclusive lab, but maybe you could get into that a little.
Aris Kekedjian: No, it’s not complicated at some level, right? I mean, the reason we partner with them and we have an exclusive arrangement as we build out our lab will be the exclusive provider for the programs that they’re working on. Their entire strategy is still B2B2C, private label. White label solutions for digital health providers, telehealth providers and players like that, okay. This is not a direct go-to-market play. They do have a website, but that’s more of a focus group operation than anything else. So, we like that model. We think that model can scale. We already do a little bit of work with them. We’re working quite closely with them to scale up that has potential and then to ramp up across a broad spectrum of tests.
Now, the pace of that is going to be €“ we’ll see what that pace is. We’re going to be careful and prudent as we roll this thing out. We’re not going to be dilutional about the complexities of getting into these types of programs. We’ve got key marquee accounts. We’re working with them on. I think it’s much more important that we have milestones with some of these marquee accounts, and execute properly on those and demonstrate that this model can work. So, I think you’ll see us ramp up the celiac test this year and roll into some of the other tests next year.
Paul Nouri: Okay. I appreciate the detail.
John Gillard: Well, in terms of money raised, they’re a private company so we’re not at liberty to say that. All I’d say is, our 1.5 investment is relatively minority, right. They significantly more than that.
Paul Nouri: Okay. All right. Thank you.
Operator: Showing no further questions. This concludes our question-and-answer session. I would like to turn the conference back over to Aris Kekedjian for any closing remarks.
